Last updated: September 27, 2026
Tafluprost is a preservative-free prostaglandin F2α analog used to reduce elevated intraocular pressure in open-angle glaucoma and ocular hypertension. The commercial opportunity is concentrated in preservative-free formulations, multidose delivery systems, generic and branded-generic launches, fixed-dose combinations, and differentiated packaging rather than in new active-ingredient chemistry. The core formulation uses a low-dose aqueous solution with glycerol, phosphate buffering, polysorbate 80 and pH adjustment agents. [1]
What is tafluprost and how is it marketed?
Tafluprost is a topical ophthalmic drug administered once daily. The U.S. reference product is Zioptan, supplied as a sterile, preservative-free ophthalmic solution in single-use containers. Tafluprost is also marketed outside the United States under names including Taflotan and Taflotan-S, depending on jurisdiction and formulation. [1,2]
| Attribute |
Tafluprost |
| Active ingredient |
Tafluprost |
| Pharmacologic class |
Prostaglandin analog |
| Typical strength |
0.0015% w/v, equivalent to 15 micrograms/mL |
| Route |
Topical ophthalmic |
| Main indications |
Open-angle glaucoma and ocular hypertension |
| Dosing |
One drop once daily |
| U.S. reference product |
Zioptan |
| U.S. sponsor |
Bausch + Lomb, following acquisition of certain ophthalmology assets |
| Preservative status |
Preservative-free |
| Primary dosage form |
Sterile aqueous ophthalmic solution |
| U.S. approval |
NDA 203092, approved in 2012 |
Tafluprost competes with latanoprost, travoprost, bimatoprost and preservative-free versions of established prostaglandin analogs. Its main clinical and commercial differentiator is the absence of benzalkonium chloride and other conventional preservatives.
What excipients are used in tafluprost ophthalmic products?
The U.S. Zioptan formulation contains glycerin, sodium phosphate dibasic, sodium phosphate monobasic, polysorbate 80, hydrochloric acid and sodium hydroxide. Water for injection is the vehicle. The formulation is adjusted to a mildly acidic pH and controlled for ophthalmic tonicity. [1]
| Excipient |
Primary formulation role |
Commercial relevance |
| Glycerin |
Tonicity modifier and humectant |
Supports ocular tolerability and isotonicity |
| Sodium phosphate dibasic |
Buffer component |
Controls pH and supports chemical stability |
| Sodium phosphate monobasic |
Buffer component |
Completes the phosphate buffer system |
| Polysorbate 80 |
Surfactant and solubilizer |
Supports wetting and uniform drug distribution |
| Hydrochloric acid |
pH adjustment |
Enables final pH control |
| Sodium hydroxide |
pH adjustment |
Enables final pH control |
| Water for injection |
Vehicle |
Provides the aqueous sterile medium |
The formulation has a narrow design space. Tafluprost is used at a very low concentration, which increases the importance of adsorption control, container compatibility, microbial control and dose uniformity. Surfactant selection also affects the risk of visible or subvisible particles, interfacial degradation and extractables from packaging components.
Why is glycerin important in tafluprost formulations?
Glycerin contributes to tonicity and may improve ocular comfort. It is widely used in ophthalmic products and has an established regulatory history. Its main limitations are viscosity effects, potential impact on drop size and compatibility with some container systems.
A tafluprost manufacturer seeking a differentiated formulation could evaluate alternative tonicity agents such as sodium chloride, mannitol or sorbitol. The commercial benefit would depend on demonstrated improvements in comfort, stability, drop size or container compatibility. A substitution without a measurable product advantage would have limited market value.
What is the role of phosphate buffering?
The phosphate system stabilizes pH during storage. It also helps maintain a reproducible product environment after opening or administration. Phosphate concentration must be balanced against ocular tolerability, precipitation risk and compatibility with packaging materials.
Alternative buffers, including citrate, borate or tromethamine systems, could create formulation and patent opportunities. Such alternatives would require comparative stability data because tafluprost degradation can be affected by pH, oxygen exposure, light and container headspace.
Why is polysorbate 80 used?
Polysorbate 80 improves wetting and helps maintain uniform distribution of the low-concentration active ingredient. It can also reduce adsorption to container surfaces. Its disadvantages include oxidative degradation, peroxide formation and potential interaction with elastomeric components.
A commercial development program should test polysorbate 80 against polysorbate 20, poloxamers, cyclodextrins and other ophthalmic-compatible solubilizers. The strongest opportunity would involve a measurable improvement in tafluprost chemical stability or a reduction in surfactant-related impurities.
What excipient strategies can differentiate tafluprost products?
The most commercially credible strategies fall into five categories: preservative-free multidose delivery, improved stability, reduced irritation, improved dose consistency and lower-cost manufacturing.
Preservative-free multidose systems
Zioptan uses single-use containers because the absence of a preservative increases contamination risk after opening. This packaging creates inconvenience, material waste and potentially higher distribution costs.
A multidose preservative-free bottle could address those limitations through:
- One-way valve systems
- Airless pump technology
- Sterile filter barriers
- Tip-sealing mechanisms
- Metered-dose ophthalmic pumps
- Container systems that prevent backflow
The formulation itself may remain substantially similar, but the delivery system can create separate device, combination-product and patent positions. The key performance requirements are microbial integrity, consistent delivered volume, low residual volume, extractables control and patient handling reliability.
Improved oxidative stability
Polysorbate 80 can generate peroxides during storage. A development program could evaluate:
- Low-peroxide-grade polysorbate 80
- Chelating agents such as disodium edetate, where justified
- Nitrogen headspace
- Light-protective packaging
- Oxygen-reducing container technology
- Alternative surfactants
- Antioxidant systems compatible with ocular administration
Any antioxidant or chelator must be assessed for ocular tolerability, preservative-free sterility, regulatory acceptability and interaction with tafluprost or the container closure system.
Reduced ocular irritation
Preservative-free tafluprost already targets patients who experience ocular surface disease or intolerance to benzalkonium chloride. Further differentiation could focus on:
- Lower buffer strength
- Optimized pH
- Reduced surfactant concentration
- Alternative tonicity systems
- Lower-volume drop delivery
- Improved formulation viscosity
- Reduced exposure to packaging-derived impurities
Clinical claims would require comparative evidence. A formulation can be commercially differentiated without a new therapeutic indication if it demonstrates lower ocular-surface burden, improved adherence or better patient preference.
Dose-volume optimization
A standard ophthalmic drop can exceed the conjunctival sac capacity, causing waste and systemic drainage. A controlled-volume system delivering approximately 20 to 30 microliters could reduce overflow and improve dose efficiency.
This opportunity is more likely to be protected through device or combination-product claims than through excipient claims alone. A smaller drop could also reduce monthly drug consumption, but the pricing model must preserve revenue per patient.
Extended-use packaging
Single-use packaging creates a large unit count per month. A compliant multidose system could reduce packaging burden and improve patient convenience. The commercial opportunity depends on whether the system can preserve sterility without adding substantial manufacturing cost.
What formulation patents could protect tafluprost products?
Tafluprost protection can arise from several patent categories:
| Patent category |
Potential protected subject matter |
Commercial effect |
| Composition patent |
Tafluprost chemical structure or salt |
Protects the active ingredient |
| Formulation patent |
Tafluprost with defined buffers, surfactants or tonicity agents |
Can delay or complicate formulation substitution |
| Stability patent |
Defined impurity limits, oxygen control or storage conditions |
Supports differentiated shelf life |
| Device patent |
Preservative-free multidose container |
Can protect commercial delivery format |
| Method-of-use patent |
Glaucoma, ocular hypertension or dosing methods |
May affect labeling and ANDA carve-outs |
| Manufacturing patent |
Purification, sterilization or filling process |
Can create supply-chain barriers |
| Packaging patent |
Single-use unit, valve, pump or container closure |
Protects product presentation and delivery |
The strongest incremental estate would combine formulation claims with device claims. A competitor could often design around a narrow excipient claim by changing the buffer, surfactant or tonicity agent. A validated device system can be harder to replace if it is tied to sterility, dose accuracy and stability performance.
What is the FDA regulatory status of tafluprost?
The FDA approved Zioptan under NDA 203092 in February 2012. The product is a sterile ophthalmic solution containing tafluprost 0.0015%. FDA labeling identifies the active ingredient and inactive ingredients and directs once-daily administration. [1]
Tafluprost is a small molecule, not a biologic. Follow-on products therefore use the abbreviated new drug application pathway rather than the biosimilar pathway. The principal regulatory issues for a generic or branded generic include:
- Pharmaceutical equivalence
- Bioequivalence or a justified ophthalmic equivalence approach
- Sterility assurance
- Container-closure integrity
- Extractables and leachables
- Impurity control
- Preservative-free handling
- Device performance where the package is integral to dosing
A formulation that changes excipients may require additional comparative characterization and stability support. A material change in delivery system can move the product toward combination-product review.
What is the Orange Book and patent status of tafluprost?
The Orange Book identifies FDA-approved drug products and, where applicable, listed patents and regulatory exclusivity. The reference product’s remaining commercial protection must be assessed against current FDA Orange Book entries, patent term adjustments, pediatric extensions and any litigation or settlement activity. [3]
Tafluprost’s core commercial opportunity is primarily post-innovator exclusivity. The active ingredient is an established small molecule, and generic competition is structurally more likely than biosimilar competition. Formulation and delivery-system patents may still affect the timing and design of competing launches.
| Protection issue |
Tafluprost relevance |
| New chemical entity exclusivity |
Historical issue; the U.S. product was approved in 2012 |
| Formulation patents |
Potentially relevant to preservative-free composition and stability |
| Method-of-use patents |
Potentially relevant to glaucoma and ocular-hypertension labeling |
| Orange Book-listed patents |
Must be checked against the current FDA listing |
| Paragraph IV risk |
Relevant to ANDA applicants challenging listed patents |
| Biosimilar risk |
Not applicable because tafluprost is a small molecule |
| Patent-term extension |
Requires product-specific review |
| Pediatric exclusivity |
Requires product-specific review |
Which companies are challenging tafluprost exclusivity?
Tafluprost competition is expected to come from generic ophthalmic manufacturers, regional branded-generic companies and companies with preservative-free glaucoma portfolios. Potential competitors include large generic manufacturers, contract development and manufacturing organizations and ophthalmic specialists.
A Paragraph IV applicant may challenge listed patents by asserting that the patent is invalid, unenforceable or not infringed. A generic applicant may also use a Paragraph III certification, wait for patent expiry or seek approval with a labeling carve-out for protected methods of use.
The commercial significance of a Paragraph IV filing depends on:
- Whether the challenged patent is listed in the Orange Book
- The remaining patent term
- The strength of the formulation claims
- The availability of an alternative formulation
- The litigation venue and settlement terms
- Whether 180-day generic exclusivity is available
- Whether the applicant can launch at risk
No biosimilar litigation framework applies to tafluprost.
What patent litigation and settlement issues affect tafluprost?
The main litigation risk concerns formulation and delivery patents rather than biologic manufacturing or interchangeability. Typical disputes could involve:
- Whether a generic composition falls within a defined surfactant or buffer range
- Whether a multidose bottle infringes a preservative-free delivery claim
- Whether the generic product uses an infringing manufacturing process
- Whether a labeling carve-out avoids method-of-use claims
- Whether a patent is enabled and adequately described
- Whether the claims are obvious in view of known prostaglandin formulations
Settlement agreements could establish a licensed entry date, authorize an alternative formulation or provide rights to supply the innovator. The business value of a settlement depends on the date of permitted generic entry and the scope of any continuing formulation restrictions.
How does tafluprost compare with competing glaucoma drugs?
| Product |
Active ingredient |
Preservative-free opportunity |
Main competitive issue |
| Zioptan |
Tafluprost |
Established single-use format |
Packaging burden and generic entry |
| Xalatan and generics |
Latanoprost |
Broad generic and PF competition |
Mature price erosion |
| Travatan Z |
Travoprost |
SofZia preservative system |
Differentiation through preservative technology |
| Lumigan |
Bimatoprost |
Preservative-free versions available |
Strong efficacy and broad competition |
| Vyzulta |
Latanoprostene bunod |
Premium branded product |
Nitric-oxide-mediated differentiation |
| Rocklatan |
Netarsudil plus latanoprost |
Combination-product opportunity |
Higher price and tolerability considerations |
Tafluprost has a clear position among preservative-free prostaglandin products, but its commercial value depends on maintaining product convenience and minimizing the cost penalty associated with single-use packaging.
What licensing and partnership opportunities exist?
Licensing opportunities are most attractive in four areas.
Preservative-free multidose technology
A device company could license a sterile multidose pump or valve system to a tafluprost manufacturer. The opportunity is strongest where the platform is already used with ophthalmic products and has established extractables, sterility and dose-uniformity data.
Generic formulation transfer
A developer with a stable tafluprost formulation could license the product to regional ophthalmology companies. The deal structure could include territorial rights, supply agreements and rights to local packaging.
Fixed-dose combination development
Tafluprost could be evaluated in combinations with timolol, carbonic anhydrase inhibitors or other glaucoma agents. The technical challenge is compatibility, preservative strategy, pH, dosing volume and regulatory support for the combination.
Contract manufacturing
Sterile ophthalmic filling capacity is constrained by specialized equipment, particulate controls and container-closure testing. A manufacturer with validated single-use filling, blow-fill-seal or multidose pump capability could capture supply agreements.
What revenue exposure and launch scenarios exist?
Tafluprost revenue is exposed to generic price erosion, packaging cost, payer substitution and the speed of preservative-free generic adoption. Three launch scenarios are commercially relevant.
| Scenario |
Product characteristics |
Expected market effect |
| Basic generic |
Same strength, aqueous solution, low-cost package |
Rapid price erosion and formulary substitution |
| Premium preservative-free generic |
PF formulation with improved usability or tolerability |
Higher price retention and specialist prescribing |
| Device-differentiated product |
Multidose PF pump with validated dose control |
Stronger brand positioning and potential lifecycle extension |
A basic generic is most vulnerable to price competition. A preservative-free multidose product has greater potential to retain value, especially in patients with ocular-surface disease, chronic topical-drug exposure or poor tolerance of preserved formulations.
How strong is the tafluprost patent estate?
The core active-ingredient estate is mature. The strongest future protection is likely to come from narrow but commercially important formulation, packaging and delivery claims.
Patent strength is highest where claims are supported by:
- A defined impurity profile
- Long-term stability data
- A specific preservative-free multidose architecture
- Demonstrated microbial integrity
- Consistent delivered dose
- Comparative tolerability data
- A manufacturing process that is difficult to replicate
Patent strength is lower where claims only recite routine excipient substitutions or broad concentration ranges without a demonstrated technical effect. Generic applicants can often design around those claims by changing the buffer, surfactant, tonicity agent or container format.
Key Takeaways
- Tafluprost is a preservative-free, once-daily ophthalmic prostaglandin analog marketed primarily as a sterile aqueous solution.
- The reference formulation uses glycerin, phosphate buffers, polysorbate 80, pH adjusters and water for injection.
- The most credible commercial opportunity is a preservative-free multidose delivery system that preserves sterility and dose accuracy.
- Formulation differentiation can focus on oxidative stability, ocular comfort, drop-volume control and packaging compatibility.
- Tafluprost is a small molecule, so generic ANDA competition applies; biosimilar competition does not.
- Core active-ingredient protection is mature, while formulation, device, manufacturing and packaging patents can support lifecycle management.
- The commercial outlook depends on the balance between generic price erosion and premium positioning for preservative-free convenience.
FAQs
Can tafluprost be formulated without polysorbate 80?
Yes. Alternative surfactants, solubilizers or surfactant-free systems can be evaluated, but the replacement must preserve tafluprost uniformity, stability, sterility and ocular tolerability.
Is a preservative-free tafluprost multidose bottle commercially feasible?
Yes. Feasibility depends on a validated sterile barrier, reliable one-way flow control, container-closure integrity, dose consistency and acceptable extractables and leachables data.
Which excipient creates the greatest formulation risk?
Polysorbate 80 presents a material risk because of oxidative degradation and peroxide formation. Its risk can be managed through raw-material controls, packaging selection, oxygen control and stability testing.
Can tafluprost be combined with timolol?
A fixed-dose tafluprost-timolol product is technically possible, but the combination would require compatibility, stability, dose-ratio, tolerability and clinical or regulatory support appropriate to the intended pathway.
Does a new tafluprost excipient combination automatically receive patent protection?
No. Patentability generally requires novelty and inventive merit. A routine substitution of one conventional ophthalmic excipient for another is vulnerable to obviousness challenges unless it produces an unexpected technical benefit.
References
- U.S. Food and Drug Administration. (2023). Zioptan (tafluprost ophthalmic solution) prescribing information.
- European Medicines Agency. (2015). Taflotan: EPAR product information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Inactive ingredient database.
- European Medicines Agency. (2023). Guideline on the quality of medicinal products for ophthalmic use.
